Access Program Information
Multiple Myeloma (MM) is the second diagnosed malignancy of hematological malignancies. The
previous study pointed out that the dosage and course of Bortezomib including the dose of
concomitant drugs used to treatment MM patients did not get the preferred treatment program,
so we are going to determine the optimal doses and course of Bortezomib through the
prospective, multicenter clinical trial and evaluate the efficiency and safety of different
program.